Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells

Papillary thyroid carcinoma contributes to about 80% of the total thyroid Cancer cases. BRaf^V600E is a frequently occurring mutation in PTCs. Although several BRaf inhibitors are available, many thyroid Cancer patients acquire resistance to BRaf inhibitors. Therefore, new targets and drugs need to be identified as therapies. Ferroptosis is a recently discovered type of cell death, and inhibiting Glutathione Peroxidase 4 (GPX4) using small molecules was found to trigger Ferroptosis. But it is unknown whether inhibiting GPX4 renders thyroid Cancer cells susceptible to Ferroptosis. To identify novel GPX4 inhibitors, we focused on our previously reported cohort of diaryl ether and dibenzoxepine molecules. In this study, we asked whether diaryl ether and dibenzoxepine derivatives trigger Ferroptosis in thyroid Cancer cells. To answer this question, we screened diaryl ether and dibenzoxepine derivatives in cell-based assays and performed mechanism of action studies. We found that a diaryl ether derivative, 16 decreased thyroid cell proliferation and triggered Ferroptosis by inhibiting GPX4 expression levels. Molecular modeling and dynamics simulations showed that 16 binds to the active site of GPX4. Upon deciphering the mode of 16-induced Ferroptosis, we found that 16 treatments decrease mitochondrial polarization and reduce mitochondrial respiration similar to a Ferroptosis inducer, RSL3. We conclude that the diaryl ether derivative, 16 inhibits GPX4 expression levels to induce Ferroptosis in thyroid Cancer cells. Based on our observations, we suggest that 16 can be lead-optimized and developed as a ferroptosis-inducing agent to treat thyroid cancers.

GPX4; ferroptosis; mitochondria; molecular docking; reactive oxygen species.